Clinical Trials Logo

Pancreatic Cancer Stage III clinical trials

View clinical trials related to Pancreatic Cancer Stage III.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05562297 Not yet recruiting - Clinical trials for Pancreatic Cancer Stage III

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research is to investigate the activity and safety of the combination of gemcitabine plus nab-paclitaxel and sintilimab as neoadjuvant therapy in treating patients with resectable and borderline resectable pancreatic cancer. The drugs involved in this study are: - Sintilimab - Nab-paclitaxel - Gemcitabine